Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kinnate Biopharma Inc (NQ: KNTE )

6.140 +0.480 (+8.48%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 145,488
Open 5.720
Bid (Size) 6.150 (2)
Ask (Size) 6.180 (7)
Prev. Close 5.660
Today's Range 5.720 - 6.220
52wk Range 3.300 - 15.86
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Kinnate Biopharma Inc. Provides Full-Year 2022 Financial Results and Recent Corporate Updates
From Kinnate Biopharma
Via Globe NewsWire
Kinnate Biopharma Inc. to Report First Clinical Data for Its Investigational Pan-RAF Inhibitor, Exarafenib (KIN-2787), in an Oral Presentation at the AACR 2023 Annual Meeting
From Kinnate Biopharma
Via Globe NewsWire

Performance

YTD
+2.16%
+2.16%
1 Month
+16.07%
+16.07%
3 Month
+14.98%
+14.98%
6 Month
-51.65%
-51.65%
1 Year
-52.99%
-52.99%

More News

Read More
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Why Bank Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Week In Review: Keymed/Lepu Sign $1.2 Billion Deal Out-Licensing Claudin 18.2 ADC To AstraZeneca
Via Talk Markets
Kinnate Biopharma Inc. Announces Acquisition of Ownership Stake from Series A Investors of the China Joint Venture, Kinnjiu Biopharma Inc., and Initiation of Phase 1 Clinical Trial for Exarafenib (KIN-2787) in People's Republic of China
From Kinnate Biopharma
Via Globe NewsWire
Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-3248, an Investigational Pan-FGFR Inhibitor
From Kinnate Biopharma
Via Globe NewsWire
Kinnate Biopharma Inc. to Participate in the 2023 SVB Securities Global Biopharma Conference
From Kinnate Biopharma
Via Globe NewsWire
Kinnate Biopharma Inc. Adds Global Business and Oncology Expertise to Board of Directors with Appointment of Jill DeSimone as Independent Director
From Kinnate Biopharma
Via Globe NewsWire
Kinnate Biopharma Inc. to Present Trials in Progress Poster for its Pan-FGFR Inhibitor, KIN-3248, at the 2023 ASCO Gastrointestinal Cancers Symposium and ASCO Genitourinary Cancers Symposium
From Kinnate Biopharma
Via Globe NewsWire
Why Inotiv Shares Dipped 57%; Here Are 76 Biggest Movers From Yesterday
Via Benzinga
Why Elevate Credit Shares Are Trading Higher By Over 71%? Here Are 43 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
BrightView Holdings, America's Car-Mart And Some Other Big Stocks Moving Lower On Thursday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2022
Via Benzinga
Walmart To Surge Around 9%? Plus B of A Securities Slashes PT On This Stock By 80%
Via Benzinga
Kinnate Biopharma Inc. Announces Third Quarter 2022 Financial Results and Recent Corporate Updates
From Kinnate Biopharma
Via Globe NewsWire
Cameco, Kinnate Biopharma And Other Big Losers From Wednesday
Via Benzinga
Silver Drops Sharply; Owens & Minor Shares Slide
Via Benzinga
Why Norwegian Cruise Line Shares Climbed By Around 12%; Here Are 66 Biggest Movers From Yesterday
Via Benzinga
Why T2 Biosystems Shares Are Trading Lower By Over 28%, Here Are 41 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Nasdaq Edges Lower; Crude Oil Down 2%
Via Benzinga
Dow Gains Over 50 Points; US Producer Prices Rise 0.4% In September
Via Benzinga
Kinnate Biopharma Inc. Announces Recent Corporate Updates, Including on the Ongoing KIN-2787 Monotherapy Dose Escalation from Global Phase 1 Trial
From Kinnate Biopharma
Via Globe NewsWire
Benzinga's Top Ratings Upgrades, Downgrades For July 28, 2022
Via Benzinga
89 Biggest Movers From Friday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.